Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications

Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01681407

Acronym

MIRPROT

Enrollment

Registered

2012-09-10

Start date

2011-11-30

Completion date

2014-02-28

Last updated

2015-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Selective Serotonin Reuptake Inhibitors, MicroRNAs, Proteome

Brief summary

A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device. The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Depressed patients,over 18 yo * Untreated with SSRI, in the last 3 months

Exclusion criteria

* Bipolar patients or another major psychopathology * Depressive disorder clearly due to general medical condition, or drug related * BMI under 18.5 or above 40 * Pregnant patients * Active suicidality

Design outcomes

Primary

Measure	Time frame
Depressive symptoms remission or response rates, under usual SSRI treatment.	10 weeks of follow up

Countries

Israel

Outcome results